Cargando…
The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry
BACKGROUND: Alpha-1-antitrypsin (AAT) deficiency (AATD) is a genetic disorder that can manifest as lung disease. A delay between onset of symptoms and diagnosis of AATD is common and associated with worse clinical status and more advanced disease stage but the influence on survival is unclear. OBJEC...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881325/ https://www.ncbi.nlm.nih.gov/pubmed/36707810 http://dx.doi.org/10.1186/s12931-023-02338-0 |
_version_ | 1784879087264727040 |
---|---|
author | Meischl, Tobias Schmid-Scherzer, Karin Vafai-Tabrizi, Florian Wurzinger, Gert Traunmüller-Wurm, Eva Kutics, Kristina Rauter, Markus Grabcanovic-Musija, Fikreta Müller, Simona Kaufmann, Norbert Löffler-Ragg, Judith Valipour, Arschang Funk, Georg-Christian |
author_facet | Meischl, Tobias Schmid-Scherzer, Karin Vafai-Tabrizi, Florian Wurzinger, Gert Traunmüller-Wurm, Eva Kutics, Kristina Rauter, Markus Grabcanovic-Musija, Fikreta Müller, Simona Kaufmann, Norbert Löffler-Ragg, Judith Valipour, Arschang Funk, Georg-Christian |
author_sort | Meischl, Tobias |
collection | PubMed |
description | BACKGROUND: Alpha-1-antitrypsin (AAT) deficiency (AATD) is a genetic disorder that can manifest as lung disease. A delay between onset of symptoms and diagnosis of AATD is common and associated with worse clinical status and more advanced disease stage but the influence on survival is unclear. OBJECTIVE: We aimed to investigate the impact of diagnostic delay on overall survival (OS) and transplant-free survival (TS) in AATD patients. METHODS: We analysed 268 AATD patients from the prospective multi-centre Austrian Alpha-1 Lung (AAL) Registry, employing descriptive statistics, Chi-square-test as well as univariable (Kaplan–Meier plots, log-rank test) and multivariable survival analysis (Cox regression). RESULTS: The predominant phenotype was Pi*ZZ (82.1%). At diagnosis, 90.2% had an AAT level below 0.6 g/L. At inclusion, 28.2% had never smoked, 68.0% had quit smoking and 3.8% continued to smoke. Lung disease was diagnosed in 98.5%, thereof most patients were diagnosed with emphysema (63.8%) and/or chronic obstructive pulmonary disease (44.0%). Median diagnostic delay was 5.3 years (inter-quartile range [IQR] 2.2–11.5 years). In multivariable analysis (n = 229), a longer diagnostic delay was significantly associated with worse OS (hazard ratio [HR] 1.61; 95% CI 1.09–2.38; p = 0.016) and TS (HR 1.43; 95% CI 1.08–1.89; p = 0.011), independent from age, smoking status, body mass index (BMI), forced expiratory volume in one second (FEV(1)) and long-term oxygen treatment. Furthermore, BMI, age and active smoking were significantly associated with worse OS as well as BMI, active smoking and FEV(1) were with worse TS. CONCLUSIONS: A delayed diagnosis was associated with significantly worse OS and TS. Screening should be improved and efforts to ensure early AATD diagnosis should be intensified. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02338-0. |
format | Online Article Text |
id | pubmed-9881325 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-98813252023-01-28 The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry Meischl, Tobias Schmid-Scherzer, Karin Vafai-Tabrizi, Florian Wurzinger, Gert Traunmüller-Wurm, Eva Kutics, Kristina Rauter, Markus Grabcanovic-Musija, Fikreta Müller, Simona Kaufmann, Norbert Löffler-Ragg, Judith Valipour, Arschang Funk, Georg-Christian Respir Res Research BACKGROUND: Alpha-1-antitrypsin (AAT) deficiency (AATD) is a genetic disorder that can manifest as lung disease. A delay between onset of symptoms and diagnosis of AATD is common and associated with worse clinical status and more advanced disease stage but the influence on survival is unclear. OBJECTIVE: We aimed to investigate the impact of diagnostic delay on overall survival (OS) and transplant-free survival (TS) in AATD patients. METHODS: We analysed 268 AATD patients from the prospective multi-centre Austrian Alpha-1 Lung (AAL) Registry, employing descriptive statistics, Chi-square-test as well as univariable (Kaplan–Meier plots, log-rank test) and multivariable survival analysis (Cox regression). RESULTS: The predominant phenotype was Pi*ZZ (82.1%). At diagnosis, 90.2% had an AAT level below 0.6 g/L. At inclusion, 28.2% had never smoked, 68.0% had quit smoking and 3.8% continued to smoke. Lung disease was diagnosed in 98.5%, thereof most patients were diagnosed with emphysema (63.8%) and/or chronic obstructive pulmonary disease (44.0%). Median diagnostic delay was 5.3 years (inter-quartile range [IQR] 2.2–11.5 years). In multivariable analysis (n = 229), a longer diagnostic delay was significantly associated with worse OS (hazard ratio [HR] 1.61; 95% CI 1.09–2.38; p = 0.016) and TS (HR 1.43; 95% CI 1.08–1.89; p = 0.011), independent from age, smoking status, body mass index (BMI), forced expiratory volume in one second (FEV(1)) and long-term oxygen treatment. Furthermore, BMI, age and active smoking were significantly associated with worse OS as well as BMI, active smoking and FEV(1) were with worse TS. CONCLUSIONS: A delayed diagnosis was associated with significantly worse OS and TS. Screening should be improved and efforts to ensure early AATD diagnosis should be intensified. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02338-0. BioMed Central 2023-01-27 2023 /pmc/articles/PMC9881325/ /pubmed/36707810 http://dx.doi.org/10.1186/s12931-023-02338-0 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Meischl, Tobias Schmid-Scherzer, Karin Vafai-Tabrizi, Florian Wurzinger, Gert Traunmüller-Wurm, Eva Kutics, Kristina Rauter, Markus Grabcanovic-Musija, Fikreta Müller, Simona Kaufmann, Norbert Löffler-Ragg, Judith Valipour, Arschang Funk, Georg-Christian The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry |
title | The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry |
title_full | The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry |
title_fullStr | The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry |
title_full_unstemmed | The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry |
title_short | The impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the Austrian Alpha-1 Lung Registry |
title_sort | impact of diagnostic delay on survival in alpha-1-antitrypsin deficiency: results from the austrian alpha-1 lung registry |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881325/ https://www.ncbi.nlm.nih.gov/pubmed/36707810 http://dx.doi.org/10.1186/s12931-023-02338-0 |
work_keys_str_mv | AT meischltobias theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT schmidscherzerkarin theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT vafaitabriziflorian theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT wurzingergert theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT traunmullerwurmeva theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT kuticskristina theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT rautermarkus theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT grabcanovicmusijafikreta theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT mullersimona theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT kaufmannnorbert theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT lofflerraggjudith theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT valipourarschang theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT funkgeorgchristian theimpactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT meischltobias impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT schmidscherzerkarin impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT vafaitabriziflorian impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT wurzingergert impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT traunmullerwurmeva impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT kuticskristina impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT rautermarkus impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT grabcanovicmusijafikreta impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT mullersimona impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT kaufmannnorbert impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT lofflerraggjudith impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT valipourarschang impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry AT funkgeorgchristian impactofdiagnosticdelayonsurvivalinalpha1antitrypsindeficiencyresultsfromtheaustrianalpha1lungregistry |